Skip to content

Study · Randomized controlled trial · 2011

5 results

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.

Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R

Diabetic medicine : a journal of the British Diabetic Association1 Mar 2011Cited by 46 (Europe PMC)

PMID21309842 (opens in a new tab)DOI10.1111/j.1464-5491.2010.03074.x (opens in a new tab)PepBankPUB-21309842
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, overall treatment satisfaction improved more with liraglutide 1.8 mg than with sitagliptin at 26 weeks (4.35 versus 2.96; P = 0.03).

    In plain wordsIn adults with type 2 diabetes on metformin, liraglutide 1.8 mg improved treatment satisfaction more than sitagliptin.

    Peptide
    Liraglutide
    Outcome
    IncreaseOverall treatment satisfaction (DTSQ), liraglutide 1.8 mg
    Study

    n: not reported in source

    Comparator
    Sitagliptin 100 mg once daily (both added to metformin)
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    improved in all groups at 26 weeks; greater improvement with liraglutide (4.35 and 3.51 vs. 2.96; P = 0.03 for liraglutide 1.8 mg vs. sitagliptin)
    2 context sentences
    Summary · context
    This patient-reported outcomes evaluation was a substudy of a 26-week randomized, open-label trial comparing the once-daily injectable human GLP-1 analogue liraglutide with once-daily oral sitagliptin, both added to metformin.
    Summary · context
    In this patient-reported outcomes substudy (liraglutide 1.8 mg, n = 171; 1.2 mg, n = 164; sitagliptin, n = 170) DTSQ scores were analyzed by ANCOVA with treatment and country as fixed effects and baseline value as covariate.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, overall treatment satisfaction improved by 3.51 with liraglutide 1.2 mg versus 2.96 with sitagliptin; the abstract gives no P value for this dose.

    In plain wordsIn adults with type 2 diabetes on metformin, satisfaction rose more with liraglutide 1.2 mg than with sitagliptin; no significance test is reported.

    Peptide
    Liraglutide
    Outcome
    IncreaseOverall treatment satisfaction (DTSQ), liraglutide 1.2 mg
    Study

    n: not reported in source

    Comparator
    Sitagliptin 100 mg once daily (both added to metformin)
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    1.2 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    improved in all groups at 26 weeks; greater improvement with liraglutide (4.35 and 3.51 vs. 2.96; P = 0.03 for liraglutide 1.8 mg vs. sitagliptin)
    2 context sentences
    Summary · context
    This patient-reported outcomes evaluation was a substudy of a 26-week randomized, open-label trial comparing the once-daily injectable human GLP-1 analogue liraglutide with once-daily oral sitagliptin, both added to metformin.
    Summary · context
    In this patient-reported outcomes substudy (liraglutide 1.8 mg, n = 171; 1.2 mg, n = 164; sitagliptin, n = 170) DTSQ scores were analyzed by ANCOVA with treatment and country as fixed effects and baseline value as covariate.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, patients perceived hyperglycaemia significantly less often with liraglutide 1.8 mg than with sitagliptin (difference = -0.88; P < 0.0001).

    In plain wordsIn adults with type 2 diabetes on metformin, patients on liraglutide 1.8 mg felt high blood sugar less often than those on sitagliptin.

    Peptide
    Liraglutide
    Outcome
    DecreasePerceived frequency of hyperglycaemia, liraglutide 1.8 mg
    Study

    n: not reported in source

    Comparator
    Sitagliptin 100 mg once daily (both added to metformin)
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients perceived themselves to be hyperglycaemic significantly less frequently with liraglutide 1.8 mg (difference = -0.88; P < 0.0001) and 1.2 mg ( -0.49; P = 0.01).
    2 context sentences
    Summary · context
    This patient-reported outcomes evaluation was a substudy of a 26-week randomized, open-label trial comparing the once-daily injectable human GLP-1 analogue liraglutide with once-daily oral sitagliptin, both added to metformin.
    Summary · context
    In this patient-reported outcomes substudy (liraglutide 1.8 mg, n = 171; 1.2 mg, n = 164; sitagliptin, n = 170) DTSQ scores were analyzed by ANCOVA with treatment and country as fixed effects and baseline value as covariate.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, patients perceived hyperglycaemia significantly less often with liraglutide 1.2 mg than with sitagliptin (difference -0.49; P = 0.01).

    In plain wordsIn adults with type 2 diabetes on metformin, patients on liraglutide 1.2 mg felt high blood sugar less often than those on sitagliptin.

    Peptide
    Liraglutide
    Outcome
    DecreasePerceived frequency of hyperglycaemia, liraglutide 1.2 mg
    Study

    n: not reported in source

    Comparator
    Sitagliptin 100 mg once daily (both added to metformin)
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    1.2 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients perceived themselves to be hyperglycaemic significantly less frequently with liraglutide 1.8 mg (difference = -0.88; P < 0.0001) and 1.2 mg ( -0.49; P = 0.01).
    2 context sentences
    Summary · context
    This patient-reported outcomes evaluation was a substudy of a 26-week randomized, open-label trial comparing the once-daily injectable human GLP-1 analogue liraglutide with once-daily oral sitagliptin, both added to metformin.
    Summary · context
    In this patient-reported outcomes substudy (liraglutide 1.8 mg, n = 171; 1.2 mg, n = 164; sitagliptin, n = 170) DTSQ scores were analyzed by ANCOVA with treatment and country as fixed effects and baseline value as covariate.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, perceived frequency of hypoglycaemia was similar across the liraglutide and sitagliptin groups.

    In plain wordsIn adults with type 2 diabetes on metformin, patients felt low blood sugar equally often with liraglutide and sitagliptin.

    Peptide
    Liraglutide
    Outcome
    No significant changePerceived frequency of hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Sitagliptin 100 mg once daily (both added to metformin)
    Outcome group
    Patient-reported outcomes · Metabolic and weight
    Studied dose
    1.2 and 1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Perceived frequency of hypoglycaemia was similar across all groups.
    2 context sentences
    Summary · context
    This patient-reported outcomes evaluation was a substudy of a 26-week randomized, open-label trial comparing the once-daily injectable human GLP-1 analogue liraglutide with once-daily oral sitagliptin, both added to metformin.
    Summary · context
    In this patient-reported outcomes substudy (liraglutide 1.8 mg, n = 171; 1.2 mg, n = 164; sitagliptin, n = 170) DTSQ scores were analyzed by ANCOVA with treatment and country as fixed effects and baseline value as covariate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 665Jun 2008 to Jun 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.